Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback